Targeting "undruggable" proteins: Design of synthetic cyclopeptides

Current Medicinal Chemistry

Volumn 23, Issue 8, 2016, Pages 748-762

  Russo, Anna ^a   Aiello, Carmela ^a   Grieco, Paolo ^a   Marasco, Daniela ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cyclopeptides; Macrocycles; Protein protein interactions

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BAMBERMYCIN; CYCLOPEPTIDE; CYCLOSPORIN; ERYTHROMYCIN; GRAMICIDIN S; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MACROCYCLIC COMPOUND; ORITAVANCIN; PEPTIDOMIMETIC AGENT; PROTEIN; RIFAMPICIN; SOMATOSTATIN; TACROLIMUS; TUBERCULOSTATIC AGENT; TYROCIDINE; CREB1 PROTEIN, HUMAN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; PROTEIN BINDING;

DRUG STRUCTURE; DRUG TARGETING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; HUMAN; SYNTHESIS;

CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DRUG DESIGN; HUMANS; MACROCYCLIC COMPOUNDS; MOLECULAR STRUCTURE; PEPTIDES, CYCLIC; PROTEIN BINDING;

EID: 84964528884     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666160112122540     Document Type: Review

References (122)

1. Zinzalla, G.; Thurston, D.E. Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. Future Med. Chem., 2009, 1(1), 65-93.
2. Ryan, D.P.; Matthews, J.M. Protein-protein interactions in human disease. Curr. Opin. Struct. Biol., 2005, 15(4), 441-446.
3. Arndt, H.D. Small molecule modulators of transcription. Angew. Chem. Int. Ed. Engl., 2006, 45(28), 4552-4560.
4. Gerrard, J.A.; Hutton, C.A.; Perugini, M.A. Inhibiting protein-protein interactions as an emerging paradigm for drug discovery. Mini Rev. Med. Chem., 2007, 7(2), 151-157.
5. Chene, P. Drugs targeting protein-protein interactions. Chem. Med. Chem., 2006, 1(4), 400-411.
6. Pawson, T.; Nash, P. Protein-protein interactions define specificity in signal transduction. Genes Dev., 2000, 14(9), 1027-1047.
7. Tsai, C.J.; Xu, D; Nussinov, R. Structural motifs at proteinprotein interfaces: protein cores versus two-state and threestate model complexes. Protein Sci., 1997, 6(9), 1793-1805.
8. Tsai, C.J.; Lin, S.L.; Wolfson, H.J.; Nussinov, R. Studies of protein-protein interfaces: a statistical analysis of the hydrophobic effect. Protein Sci., 1997, 6(1), 53-64.
9. Young, L.; Jernigan, R.L.; Covell, D.G. A role for surface hydrophobicity in protein-protein recognition. Protein Sci., 1994, 3(5), 717-729.
10. Norel, R.; Sheinerman, F.; Petrey, D.; Honig, B. Electrostatic contributions to protein-protein interactions: fast energetic filters for docking and their physical basis. Protein Sci., 2001, 10(11), 2147-2161.
11. Sheinerman, F.B.; Honig, B. On the role of electrostatic interactions in the design of protein-protein interfaces. J. Mol. Biol., 2002, 318(1), 161-177.
12. Sheinerman, F.B.; Norel, R.; Honig, B. Electrostatic aspects of protein-protein interactions. Curr. Opin. Struct. Biol., 2000, 10(2), 153-159.
13. Xu, D.; Lin, S.L.; Nussinov, R. Protein binding versus protein folding: the role of hydrophilic bridges in protein associations. J. Mol. Biol., 1997, 265(1), 68-84.
14. Lenaerts, T.; Schymkowitz, J.; Rousseau, F. Protein domains as information processing units. Curr. Protein Pept. Sci., 2009, 10(9), 133-145.
15. Marasco, D.; Scognamiglio, P.L. Identification of inhibitors of biological interactions involving intrinsically disordered proteins. Int. J. Mol. Sci., 2015, 16(4), 7394-7412.
16. Nooren, I.M.; Thornton J.M. Diversity of protein-protein interactions. EMBO J., 2003, 22(14), 3486-3492.
17. Monod, J.; Wyman, J.; Changeux, J.P. On the nature of allosteric transitions: a plausible model. J. Mol. Biol., 1965, 12, 88-118.
18. Goodsell, D.S.; Olson, A.J. Structural symmetry and protein function. Annu. Rev. Biophys. Biomol. Struct., 2000, 29, 105-153.
19. Dill, K.A.; Fiebig, K.M.; Chan, H.S. Cooperativity in protein-folding kinetics. Proc. Natl. Acad. Sci. U S A, 1993, 90(5), 1942-1946.
20. Kolinski, A.; Galazka, W.; Skolnick, J. On the origin of the cooperativity of protein folding: implications from model simulations. Proteins, 1996, 26(3), 271-287.
21. Tsai, C.J.; Nussinov, R. Hydrophobic folding units at protein-protein interfaces: implications to protein folding and to protein-protein association. Protein Sci., 1997, 6(7), 1426-1437.
22. Keskin, O.; Gursoy, A.; Ma, B.; Nussinov, R. Principles of protein-protein interactions: what are the preferred ways for proteins to interact? Chem. Rev., 2008, 108(4), 1225-1244.
23. Cheng, A.C.; Coleman, R.G.; Smyth, K.T.; Cao, Q.; Soulard, P.; Caffrey, D.R.; Salzberg, A.C.; Huang, E.S. Structure-based maximal affinity model predicts smallmolecule druggability. Nat. Biotechnol., 2007, 25(1), 71-75.
24. Keskin, O.; Ma, B.; Nussinov, R. Hot regions in protein - protein interactions: the organization and contribution of structurally conserved hot spot residues. J. Mol. Biol., 2005, 345(5), 1281-1294.
25. Li, X.; Keskin, O.; Ma, B.; Nussinov, R.; Liang, J. Proteinprotein interactions: hot spots and structurally conserved residues often locate in complemented pockets that preorganized in the unbound states: implications for docking. J. Mol. Biol., 2004, 344(3), 781-795.
26. Northrup, S.H.; Boles, J.O.; Reynolds, J.C. Brownian dynamics of cytochrome c and cytochrome c peroxidase association. Science, 1988, 241(4861), 67-70.
27. Schilder, J.; Ubbink, M. Formation of transient protein complexes. Curr. Opin. Struct. Biol., 2013, 23(6), 911-988.
28. Wells, J.A.; McClendon, C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature, 2007, 450(7172), 1001-1009.
29. Sudha, G.; Nussinov, R.; Srinivasan, N. An overview of recent advances in structural bioinformatics of proteinprotein interactions and a guide to their principles. Prog. Biophys. Mol. Biol., 2014, 116, 141-150.
30. Ruiz-Gomez, G.; Tyndall, J.D.; Pfeiffer, B.; Abbenante, G.; Fairlie, D.P. Update 1 of: Over one hundred peptideactivated G protein-coupled receptors recognize ligands with turn structure. Chem. Rev., 2010, 110(4), R1-R41.
31. Whitby, L.R.; Ando, Y.; Setola, V.; Vogt, P.K.; Roth, B.L.; Boger, D.L. Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactions. J. Am. Chem. Soc., 2011, 133(26), 10184-10194.
32. Vagner, J.; Qu, H.; Hruby, V.J. Peptidomimetics, a synthetic tool of drug discovery. Curr. Opin. Chem. Biol., 2008, 12(3), 292-296.
33. Nie, Q.; Du,X.G.; Geng, M.Y. Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease. Acta Pharmacol. Sin., 2011, 32(5), 545-551.
34. Azzarito, V.; Long, K.; Murphy, N.S.; Wilson, A.J. Inhibition of alpha-helix-mediated protein-protein interactions using designed molecules. Nat. Chem., 2013, 5(3), 161-173.
35. Chrencik, J.E.; Brooun, A.; Recht, M.I.; Kraus, M.L.; Koolpe, M.; Kolatkar, A.R.; Bruce, R.H.; Martiny-Baron, G.; Widmer, H.; Pasquale, E.B.; Kuhn, P. Structure and thermodynamic characterization of the EphB4/ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. Structure, 2006, 14(2), 321-330.
36. Guharoy, M.; Chakrabarti, P. Secondary structure based analysis and classification of biological interfaces: identification of binding motifs in protein-protein interactions. Bioinformatics, 2007, 23(15), 1909-1918.
37. Gavenonis, J.; Sheneman, B.A.; Siegert, T.R.; Eshelman, M.R.; Kritzer, J.A. Comprehensive analysis of loops at protein-protein interfaces for macrocycle design. Nat. Chem. Biol. 2014, 10(9), 716-722.
38. Vollmuth, F.; Blankenfeldt, W.; Geyer, M. Structures of the dual bromodomains of the P-TEFb-activating protein Brd4 at atomic resolution. J. Biol. Chem., 2009, 284(52), 36547-36556.
39. Villar, E.A.; Beglov, D.; Chennamadhavuni, S.; Porco, J.A. Jr.; Kozakov, D.; Vajda, S.; Whitty, A. How proteins bind macrocycles. Nat. Chem. Biol., 2014, 10(9), 723-731.
40. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2012, 64, 4-17.
41. Giordanetto, F.; Kihlberg, J. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? J. Med. Chem., 2014, 57(2), 278-295.
42. Wessjohann, L.A. Synthesis of natural-product-based compound libraries. Curr. Opin. Chem. Biol., 2000, 4(3), 303-309.
43. Butler, M.S. Natural products to drugs: natural productderived compounds in clinical trials. Nat. Prod. Rep., 2008, 25(3), 475-516.
44. Butler, M.S.; Buss, A.D. Natural products - the future scaffolds for novel antibiotics? Biochem. Pharmacol., 2006, 71(7), 919-929.
45. Nghiem, P.; Pearson, G.; Langley, R.G. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J. Am. Acad. Dermatol., 2002, 46(2), 228-241.
46. Bartlett, S.; Beddard, G.S.; Jackson, R.M.; Kayser, V.; Kilner, C.; Leach, A.; Nelson, A.; Oledzki, P.R.; Parker, P.; Reid, G.D.; Warriner, S.L. Comparison of the ATP binding sites of protein kinases using conformationally diverse bisindolylmaleimides. J. Am. Chem. Soc., 2005, 127(33), 11699-11708.
47. White, C.J.; Yudin, A.K. Contemporary strategies for peptide macrocyclization. Nat. Chem., 2011, 3(7), 509-524.
48. Katsara, M.; Tselios, T.; Deraos, S.; Deraos, G.; Matsoukas, M.T.; Lazoura, E.; Matsoukas, J.; Apostolopoulos, V. Round and round we go: cyclic peptides in disease. Curr. Med. Chem., 2006, 13(19), 2221-2232.
49. Jiang, S.; Li, Z.; Ding, K.; Roller, P.P. Recent progress of synthetic studies to peptide and peptidomimetic cyclization. Curr. Org. Chem., 2008, 12(17), 1502-1542.
50. Driggers, E.M.; Hale, S.P.; Lee, J.; Terrett, N.K. The exploration of macrocycles for drug discovery - an underexploited structural class. Nat. Rev. Drug Discov., 2008, 7, 608-624.
51. Montalbetti, C.; Falque, V. Amide bond formation and peptide coupling. Tetrahedron, 2005, 61(46), 10827-10852.
52. Parenty, A.; Moreau, X; Campagne, J.M. Macrolactonizations in the total synthesis of natural products. Chem. Rev., 2006, 106(3), 911-939.
53. Gongora-Benitez, M.; Tulla-Puche, J.; Albericio, F. Multifaceted roles of disulfide bonds. Peptides as therapeutics. Chem. Rev., 2014, 114(2), 901-926.
54. Lundquist, J.T. 4th; Pelletier, J.C. A new tri-orthogonal strategy for peptide cyclization. Org. Lett., 2002, 4(19), 3219-3221.
55. Diener, M.E.; Metrano, A.J.; Kusano, S.; Miller, S.J. Enantioselective synthesis of 3-arylquinazolin-4(3H)-ones via peptide-catalyzed atroposelective bromination. J. Am. Chem. Soc., 2015, 137(38), 12369-12377.
56. Kawamoto, S.A.; Coleska, A.; Ran, X.; Yi, H.; Yang, C.Y.; Wang, S. Design of triazole-stapled BCL9 alpha-helical peptides to target the beta-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction. J. Med. Chem., 2012, 55(3), 1137-1146.
57. Jacobsen, O.; Klaveness, J.; Rongved, P. Structural and pharmacological effects of ring-closing metathesis in peptides. Molecules, 2010, 15(9), 6638-6677.
58. Malesevic, M.; Strijowski, U.; Bachle, D. An improved method for the solution cyclization of peptides under pseudo-high dilution conditions. J. Biotechnol., 2004, 112(1-2), 73-77.
59. Bhattacharyya, S. New developments in polymer-supported reagents, scavengers and catalysts for organic synthesis. Curr. Opin. Drug Discov. Devel., 2004, 7(6), 752-764.
60. Bhattacharyya, S. Polymer-supported reagents and catalysts: recent advances in synthetic applications. Comb. Chem. High Throughput Screen., 2000, 3(2), 65-92.
61. Marsault, E.; Hoveyda, H.R.; Peterson, M.L.; Gagnon, R.; Vezina, M.; Pinault, J.F.; Landry, A.; Saint-Louis, C.; Ouellet, L.G.; Beauchemin, S.; Benakli, K.; Beaubien, S.; Brassard, M.; Wang, Z.; Champagne, M.; Galaud, F.; Fortin, N.; Fortin, D.; Plourde, V.; Ramaseshan, M.; Bhat, S.; Bilodeau, F.; Lonergan, D.; Lan, R.; Li, S.; Berthiaume, G.; Foucher, L.; Peng, X.; Dory, Y.; Deslongchamps, P. High throughput solid phase parallel synthesis of macrocyclic peptidomimetics. Adv. Exp. Med. Biol., 2009, 611, 15-16.
62. Schmidt, U.; Langner, J. Cyclotetrapeptides and cyclopentapeptides: occurrence and synthesis. J. Pept. Res., 1997, 49(1), 67-73.
63. Daidone, I.; Neuweiler, H.; Doose, S.; Sauer, M.; Smith, J.C., Hydrogen-bond driven loop-closure kinetics in unfolded polypeptide chains. PLoS Comp. Biol., 2010, 6(1), e1000645.
64. Favre, M.; Jiang, L.; Robinson, J.A.; Moehle, K. Structural mimicry of canonical conformations in antibody hypervariable loops using cyclic peptides containing a heterochiral diproline template. J. Am. Chem. Soc., 1999, 121(12), 2679-2685.
65. Dumy, P.; Keller, M.; Ryan, D.E.; Rohwedder, B.; Wohr, T.; Mutter, M. Pseudo-Prolines as a Molecular Hinge: Reversible induction of cis amide bonds into peptide backbones. J. Am. Chem. Soc., 1997, 119(5), 918-925.
66. Amore, A.; van Heerbeek, R.; Zeep, N.; van Esch, J.; Reek, J.N.; Hiemstra, H.; van Maarseveen, J.H. Carbosilane dendrimeric carbodiimides: site isolation as a lactamization tool. J. Org. Chem., 2006, 71(5), 1851-1860.
67. Haas, K.; Ponikwar, W.; Noeth, H.; Beck,W. Facile synthesis of cyclic tetrapeptides from nonactivated peptide esters on metal centers. Angew. Chem. Int. Ed. Engl., 1998, 37(8), 1086-1089.
68. Skropeta, D.; Jolliffe, K.A.; Turner, P. Pseudoprolines as removable turn inducers: tools for the cyclization of small peptides. J. Org. Chem., 2004, 69(25), 8804-8809.
69. Koopmanschap, G.; Ruijter, E.; Orru, R.V. Isocyanidebased multicomponent reactions towards cyclic constrained peptidomimetics. Beilstein J. Org. Chem., 2014, 10, 544-598.
70. Toniolo, C.; Crisma, M.; Moretto, A.; Peggion, C.; Formaggio, F.; Aleman, C.; Cativiela, C.; Ramakrishnan, C.; Balaram, P. Peptide δ-turn: literature survey and recent progress. Chemistry, 2015, 21(40), 13866-13877.
71. Walensky, L.D.; Bird, G.H. Hydrocarbon-stapled peptides: principles, practice, and progress. J. Med. Chem., 2014, 57(15), 6275-6288.
72. Lau, Y.H.; de Andrade, P.; Wu, Y.; Spring, D.R. Peptide stapling techniques based on different macrocyclisation chemistries. Chem. Soc. Rev., 2015, 44(1), 91-102.
73. Pomilio, A.B.; Battista, M.E.; Vitale, A.A. Naturallyoccurring cyclopeptides: Structures and bioactivity. Curr. Org. Chem., 2006, 10(16), 2075-2121.
74. Trabi, M.C.; Craik, D.J. Circular proteins - no end in sight. Trends Biochem. Sci., 2002, 27(3), 132-138.
75. Pomilio A.B.; Battista, S.M.; Vitale, A.A. Antimicrobial and immunosuppressive activitites of cyclopeptides as targets for medicinal chemistry. In: Chemometrics Applications and Research: QSAR in Medicinal Chemistry. Mercader, A.G.; Duchowicz, P.R.; Sivakumar, P.M.; Eds. Apple Academic Press Inc., exclusive worldwide distribution by CRC Press, a Taylor & Francis Group, 2015. ISBN: 978-1-77188-113-5
76. Pomilio A.B.; Battista, S.M.; Vitale, A.A. Quantitative structure-activity relationship (QSAR) studies on bioactive cyclopeptides. In: QSPR-QSAR Studies on desired properties for drug design. Castro, E.A.; chief editor. Pandalai, S.G.; Managing Ed. Research Signpost: Kerala, India, 2010; Chapter 1, pp. 1-34. ISBN: 978-81-308-0404-0. http://issuu.com/researchsignpost/docs/castro-e-book
77. Martinez Viedma, P.; Abriouel, H.; Omar, N.B.; Lopez, R.L.; Galvez, A. Inhibition of spoilage and toxigenic Bacillus species in dough from wheat flour by the cyclic peptide enterocin AS-48. Food Control, 2011, 22(5), 756-761.
78. Borrero, J.; Brede, D.A.; Skaugen, M.; Diep, D.B.; Herranz, C.; Nes, I.F.; Cintas, L.M.; Hernandez, P.E. Characterization of garvicin ML, a novel circular bacteriocin produced by Lactococcus garvieae DCC43, isolated from mallard ducks (Anas platyrhynchos). Appl. Environ. Microb., 2011, 77(1), 369-373.
79. Sawa, N.; Zendo, T.; Kiyofuji, J.; Fujita, K.; Himeno, K.; Nakayama, J.; Sonomoto, K. Identification and characterization of lactocyclicin Q, a novel cyclic bacteriocin produced by Lactococcus sp. strain QU 12. Appl. Environ. Microb., 2009, 75(6), 1552-1558.
80. Gruber, C.W.; Elliott, A.G.; Ireland, D.C.; Delprete, P.G.; Dessein, S.; Goransson, U.; Trabi, M.; Wang, C.K.; Kinghorn, A.B.; Robbrecht, E.; Craik, D.J. Distribution and evolution of circular miniproteins in flowering plants. The Plant Cell, 2008, 20(9), 2471-2483.
81. Koehbach, J; O'Brien, M.; Muttenthaler, M.; Miazzo, M.; Akcan, M.; Elliott, A.G.; Daly, N.L.; Harvey, P.J.; Arrowsmith, S.; Gunasekera, S.; Smith, T.J.; Wray, S.; Goransson, U.; Dawson, P.E.; Craik, D.J.; Freissmuth, M.; Gruber, C.W. Oxytocic plant cyclotides as templates for peptide G protein-coupled receptor ligand design. Proc. Natl. Acad. Sci. U S A, 2013, 110(52), 21183-21188.
82. Venkataraman, N.; Cole, A. L.; Ruchala, P.; Waring, A. J.; Lehrer, R. I.; Stuchlik, O.; Pohl, J.; Cole, A.M. Reawakening retrocyclins: ancestral human defensins active against HIV-1. PLoS Biol., 2009, 7(4), 0720-0729.
83. Dubos, R.J.; Cattaneo, C. Studies on a bactericidal agent extracted from a soil bacillus: III. Preparation and activity of a protein-free fraction. J. Exp. Med., 1939, 70(3), 249-256.
84. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature, 2002, 415(6870), 389-395.
85. Marques, M.A.; Citron, D.M.; Wang, C.C. Development of Tyrocidine A analogues with improved antibacterial activity. Bioorg. Med. Chem., 2007, 15(21), 6667-6677.
86. Ruegger, A.; Kuhn, M.; Lichti, H.; Loosli, H.R., Huguenin, R., Quiquerez, C.; von Wartburg, A. Cyclosporin A, a peptide metabolite from trichoderma polysporum (Link ex Pers.) Rifai, with a remarkable immunosuppressive activity. Helv. Chim. Acta, 1976, 59(4), 1075-1092.
87. Liu, W.T.; Marat, K.; Ren, Y.; Eng, R.T.; Wong, P.Y. Structural characterization of two novel oxidative derivatives of cyclosporine generated by a chemical method. Clin. Biochem., 1998, 31(3), 173-180.
88. Naicker, S.; Yatscoff, R.W.; Foster, R.T. Methods of making deuterated cyclosporin analogs, 2009, patents/US7538189, Isotechnika Inc.
89. Balsley, M.A.; Malesevic, M.; Stemmy, E.J.; Gigley, J.; Jurjus, R.A.; Herzog, D.; Bukrinsky, M.I.; Fischer, G.; Constant, S.L. A cell-impermeable cyclosporine A derivative reduces pathology in a mouse model of allergic lung inflammation. J. Immunol., 2010, 185(12), 7663-7670.
90. Boger, D.L. Vancomycin, teicoplanin, and ramoplanin: synthetic and mechanistic studies. Med. Res. Rev., 2001, 21(5), 356-381.
91. Knox, J.R.; Pratt, R.F. Different modes of vancomycin and D-alanyl-D-alanine peptidase binding to cell wall peptide and a possible role for the vancomycin resistance protein. Antimicrob. Agents Chemother., 1990, 34(7), 1342-1347.
92. ten Brink, H.T.; Rijkers, D.T.; Liskamp, R.M. Synthesis of alkyne-bridged cyclic tripeptides toward constrained mimics of vancomycin. J. Org. Chem., 2006, 71(5), 1817-1824.
93. Okano, A.; Nakayama, A.; Schammel, A.W.; Boger, D.L. Total synthesis of [Psi[C( horizontal lineNH)NH]Tpg (4)]vancomycin and its (4-chlorobiphenyl)methyl derivative: impact of peripheral modifications on vancomycin analogues redesigned for dual D-Ala-D-Ala and D-Ala-D-Lac binding. J. Am. Chem. Soc., 2014, 136(39), 13522-13525.
94. Ge, M.; Chen, Z.; Onishi, H.R.; Kohler, J.; Silver, L.L.; Kerns, R.; Fukuzawa, S.; Thompson, C.; Kahne, D. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science, 1999, 284(5413), 507-511.
95. Fusetani, N.; Matsunaga, S. Bioactive sponge peptides. Chem. Rev., 1993, 93(5), 1793-1806.
96. Maryanoff, B.E.; Zhang, H.C.; Greco, M.N.; Glover, K.A.; Kauffman, J.A.; Andrade-Gordon, P. Cyclotheonamide derivatives: synthesis and thrombin inhibition. Exploration of specific structure-function issues. Bioorg. Med. Chem., 1995, 3(8), 1025-1038.
97. Joo, S.H. Cyclic peptides as therapeutic agents and biochemical tools. Biomol. Ther., 2012, 20(1), 19-26.
98. Gehlsen, K.R.; Argraves, W.S.; Pierschbacher, M.D.; Ruoslahti, E. Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides. J. Cell. Biol., 1988, 106(3), 925-930.
99. Gurrath, M.; Muller, G.; Kessler, H.; Aumailley, M.; Timpl, R., Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur. J. Biochem., 1992, 210(3), 911-921.
100. Noiri, E., Gailit, J.; Sheth, D.; Magazine, H.; Gurrath, M.; Muller, G.; Kessler, H.; Goligorsky, M.S. Cyclic RGD peptides ameliorate ischemic acute renal failure in rats. Kidney Int., 1994, 46(4), 1050-1058.
101. Zhang, Z.; Ni, J.; Chen, L.; Yu, L.; Xu, J.; Ding, J. Encapsulation of cell-adhesive RGD peptides into a polymeric physical hydrogel to prevent postoperative tissue adhesion. J. Biomed. Mater. Res., Part B, 2012, 100B(6), 1599-1609.
102. Sugo, T.; Murakami, Y.; Shimomura, Y.; Harada, M., Abe, M.; Ishibashi, Y.; Kitada, C.; Miyajima, N.; Suzuki, N.; Mori, M.; Fujino, M. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem. Biophys. Res. Commun., 2003, 310(3), 860-868.
103. Bianca, R.; Mitidieri, E.; Fusco, F.; D'Aiuto, E.; Grieco, P.; Novellino, E.; Imbimbo, C.; Mirone, V.; Cirino, G.; Sorrentino, R. Endogenous urotensin II selectively modulates erectile function through eNOS. PloS One, 2012, 7(2), e31019.
104. Grieco, P.; Carotenuto, A.; Campiglia, P.; Zampelli, E.; Patacchini, R.; Maggi, C.A.; Novellino, E.; Rovero, P. A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. J. Med. Chem., 2002, 45(20), 4391-4394.
105. Grieco, P.; Carotenuto, A.; Patacchini, R.; Maggi, C.A.; Novellino, E.; Rovero, P. Design, synthesis, conformational analysis, and biological studies of urotensin-II lactam analogues. Bioorg. Med. Chem., 2002, 10(12), 3731-3739.
106. Carotenuto, A.; Auriemma, L.; Merlino, F.; Yousif, A.M.; Marasco, D.; Limatola, A.; Campiglia, P., Gomez-Monterrey, I.; Santicioli, P.; Meini, S.; Maggi, C.A.; Novellino, E.; Grieco, P. Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor. J. Med. Chem., 2014, 57(14), 5965-5974.
107. Zhang, J.; Yamaguchi, S.; Nagamune, T. Sortase Amediated synthesis of ligand-grafted cyclized peptides for modulating a model protein-protein interaction. Biotechnol. J., 2015, 10(9), 1499-1505.
108. Scognamiglio, P.L.; Di Natale, C.; Perretta, G.; Marasco, D. From peptides to small molecules: an intriguing but intricated way to new drugs. Curr. Med. Chem., 2013, 20(31), 3803-3817.
109. Scognamiglio, P.L.; Morelli, G.; Marasco, D. Synthetic and structural routes for the rational conversion of peptides into small molecules. Methods Mol. Biol., 2015, 1268(10), 159-193.
110. Tyndall, J.D.; Reid, R.C.; Tyssen, D.P.; Jardine, D.K.; Todd, B.; Passmore, M.; March, D.R.; Pattenden, L.K.; Bergman, D.A.; Alewood, D.; Hu, S.H.; Alewood, P.F.; Birch, C.J.; Martin, J.L.; Fairlie, D.P. Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease. J. Med. Chem., 2000, 43(19), 3495-3504.
111. Roviello, G.N.; Musumeci, D.; Roviello, V. Cationic peptides as RNA compaction agents: a study on the polyA compaction activity of a linear alpha,epsilon-oligo-L-lysine. Int. J. Pharm., 2015, 485(1-2), 244-248.
112. Roviello, G.N.; Musumeci, D.; Roviello, V.; Pirtskhalava, M.; Egoyan, A.; Mirtskhulava, M. Natural and artificial binders of polyriboadenylic acid and their effect on RNA structure. Beilstein J. Nanotechnol., 2015, 6, 1338-1347.
113. Wang, C.K.; Northfield, S.E.; Colless, B.; Chaousis, S.; Hamernig, I.; Lohman, R.J.; Nielsen, D.S.; Schroeder, C.I.; Liras, S.; Price, D.A.; Fairlie, D.P., Craik, D.J. Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients. Proc. Natl. Acad. Sci. USA, 2014, 111(49), 17504-17509.
114. Qian, Z.; Xu, X.; Amacher, J.F.; Madden, D.R.; Cormet-Boyaka, E.; Pei, D. Intracellular delivery of peptidyl ligands by reversible cyclization: discovery of a PDZ domain inhibitor that rescues CFTR activity. Angew. Chem., 2015, 54(20), 5874-5878.
115. Gao, M.; Londonb, N.; Chengc, K.; Tamurac, R.; Jina, J.; Schueler-Furmanb, O.; Yina, H. Rationally designed macrocyclic peptides as synergistic agonists of LPSinduced inflammatory response. Tetrahedron, 2014, 70(42), 7664-7668.
116. Zachariassen, Z.G.; Thiele, S.; Berg, E.A.; Rasmussen, P.; Fossen, T.; Rosenkilde, M,M.; Vabeno, J.; Haug, B.E. Design, synthesis, and biological evaluation of scaffoldbased tripeptidomimetic antagonists for CXC chemokine receptor 4 (CXCR4). Bioorg. Med. Chem., 2014, 22(17), 4759-4769.
117. Gentilucci, L.; Tolomelli, A.; De Marco, R.; Spampinato, S.; Bedini, A.; Artali, R. The inverse type II beta-turn on DTrp-Phe, a pharmacophoric motif for MOR agonists. Chem. Med. Chem., 2011, 6(9), 1640-1653.
118. Gerona-Navarro, G.; Yoel-Rodriguez; Mujtaba, S.; Frasca, A.; Patel, J.; Zeng, L.; Plotnikov, A.N.; Osman, R.; Zhou, M.M. Rational design of cyclic peptide modulators of the transcriptional coactivator CBP: a new class of p53 inhibitors. J. Am. Chem. Soc., 2011, 133(7), 2040-2043.
119. Yousif, A.M.; Minopoli, M.; Bifulco, K.; Ingangi, V.; Di Carluccio, G.; Merlino, F.; Motti, M.L.; Grieco, P.; Carriero, M.V. Cyclization of the urokinase receptorderived ser-arg-ser-arg-tyr Peptide generates a potent inhibitor of trans-endothelial migration of monocytes. PloS One, 2015, 10(5), e0126172.
120. Kaltofen, S.; Li, C.; Huang P.S.; Serpell, L.C. Barth, A.; Andre, I. Computational de novo design of a selfassembling peptide with predefined structure. J. Mol. Biol., 2015, 427(2), 550-62.
121. Burgess, N.C.; Sharp, T.H.; Thomas, F.; Wood, C.W.; Thomson, A.R.; Zaccai, N.R.; Brady, R.L.; Serpell, L.C.; Woolfson, D.N. Modular design of self-assembling peptidebased nanotubes. J. Am. Chem. Soc., 2015, 137(33), 10554-10562.
122. Roxin, A.; Zheng, G. Flexible or fixed: a comparative review of linear and cyclic cancer-targeting peptides. Future Med. Chem., 2012, 4(12), 1601-1618.